LONG-TERM SAFETY OF VEDOLIZUMAB FOR THE TREATMENT OF ULCERATIVE COLITIS OR CROHN’S DISEASE

(1) Icahn School of Medicine at Mount Sinai

(2) University of Chicago Medical Center

(3) Katholieke Universiteit and University Hospital Gasthuisberg

(4) University of California San Diego

(5) Istituto Clinico Humanitas

(6) Academic Medical Center

(7) University of Calgary

(8) Millennium Pharmaceuticals, Inc

(9) Takeda Pharmaceuticals International, Inc

(10) Robarts Research Institute, University of Western Ontario



This item was part of the Safety profile of immunosuppressive therapy in IBD session at UEG Week 2013

This item can be cited as: United European Gastroenterology Journal; 2013: 1 (Supplement 1) A107

You may be interested in:

AbbVie - Are we ready to change the course of IBD?
English, Presentation, Industry Sponsored Symposia, Industry Sponsored Symposia, 2018, AbbVie
LONG-TERM SAFETY OF VEDOLIZUMAB FOR THE TREATMENT OF ULCERATIVE COLITIS OR CROHN’S DISEASE
English, Medical management, Inflammatory bowel disease, Abstract, 'IBD-ology', 2013

Categorisation:

  • Clinical Specialty
    • 'IBD-ology'
  • Diagnosis and Management
    • Medical management
  • Disease
    • Inflammatory bowel disease
  • Format
    • Abstract
  • Language
    • English
  • Year
    • 2013